GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kraig Biocraft Laboratories KBLB · USD

Materials · US listing · 🇺🇸 United States

Compare

0.08

+1.49%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

—

FY2016FY2025

Net income

−$3.6m

FY2016FY2025

Free cash flow

−$1.8m

FY2016FY2025

Shareholders' equity

−$8.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue———————$401,620$97,318$31,858
Gross profit———————$401,620$97,318$31,858
Research and development$165,758$164,374$237,871$176,431$197,745$88,470$223,050$148,069$258,892$397,136
Operating income−$3.4m−$3.1m−$2.6m−$2.1m−$2.8m−$4.5m−$2.6m−$959,947−$2.2m−$2.9m
Net income−$3.6m−$3.4m−$3.0m−$3.8m−$8.0m−$5.0m−$2.9m−$1.2m−$2.3m−$3.1m
Diluted earnings per share-0.00-0.00-0.00-0.00-0.01-0.01-0.00-0.00-0.00-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$2.6m$1.5m$3.2m$4.6m$3.0m$1.3m$750,850$71,383$114,499$383,659
Total liabilities$10.6m$9.7m$8.9m$8.1m$8.3m$7.9m$6.1m$4.5m$3.5m$2.7m
Debt————$95,244$145,244$887,244———
Shareholders' equity−$8.0m−$8.1m−$5.7m−$3.5m−$5.3m−$6.6m−$5.4m−$4.5m−$3.4m−$2.4m
Shares outstanding1,084m1,038m1,038m1,031m927m854m844m817m817m500m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$1.8m−$1.8m−$1.2m−$1.9m−$1.8m−$1.3m−$1.1m−$235,005−$729,542−$1.0m
Capital spending−$5,395−$4,240−$6,399−$5,021−$97,154−$97,154−$100,792−$11,448−$31,167−$2,488
Free cash flow−$1.8m−$1.8m−$1.3m−$1.9m−$1.9m−$1.4m−$1.2m−$246,453−$760,709−$1.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Operating income−$703,433−$825,500−$722,668−$1.4m−$637,745−$580,492−$715,916−$423,797
Net income−$909,535−$942,720−$787,621−$1.5m−$726,133−$600,033−$851,675−$433,200
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$4.3m$3.7m$2.6m$2.4m$1.6m$1.3m$1.5m$2.0m
Shareholders' equity−$6.8m−$7.1m−$8.0m−$8.0m−$8.5m−$8.5m−$8.1m−$7.4m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income16.7%-5.7%5.1%
Net income-1.9%-6.1%5.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-26.9-27.5-13.7-8.1-9.2-22.3-35.7-22.6-9.1-5.3
Price to sales———————65.8217.3—

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-11%135%33%-70%-23%6%280%25%-20%150%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-for-1 split · 28 May 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.